FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 123 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |